Literature DB >> 29950444

Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy.

Thomas C Thannickal1,2, Joshi John1,2, Ling Shan1,2, Dick F Swaab3, Ming-Fung Wu1,2, Lalini Ramanathan1,2, Ronald McGregor1,2, Keng-Tee Chew1,2, Marcia Cornford4, Akihiro Yamanaka5, Ayumu Inutsuka5, Rolf Fronczek6,7, Gert Jan Lammers6,7, Paul F Worley8, Jerome M Siegel9,2.   

Abstract

The changes in brain function that perpetuate opiate addiction are unclear. In our studies of human narcolepsy, a disease caused by loss of immunohistochemically detected hypocretin (orexin) neurons, we encountered a control brain (from an apparently neurologically normal individual) with 50% more hypocretin neurons than other control human brains that we had studied. We discovered that this individual was a heroin addict. Studying five postmortem brains from heroin addicts, we report that the brain tissue had, on average, 54% more immunohistochemically detected neurons producing hypocretin than did control brains from neurologically normal subjects. Similar increases in hypocretin-producing cells could be induced in wild-type mice by long-term (but not short-term) administration of morphine. The increased number of detected hypocretin neurons was not due to neurogenesis and outlasted morphine administration by several weeks. The number of neurons containing melanin-concentrating hormone, which are in the same hypothalamic region as hypocretin-producing cells, did not change in response to morphine administration. Morphine administration restored the population of detected hypocretin cells to normal numbers in transgenic mice in which these neurons had been partially depleted. Morphine administration also decreased cataplexy in mice made narcoleptic by the depletion of hypocretin neurons. These findings suggest that opiate agonists may have a role in the treatment of narcolepsy, a disorder caused by hypocretin neuron loss, and that increased numbers of hypocretin-producing cells may play a role in maintaining opiate addiction.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29950444      PMCID: PMC8235614          DOI: 10.1126/scitranslmed.aao4953

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  38 in total

1.  Highly specific role of hypocretin (orexin) neurons: differential activation as a function of diurnal phase, operant reinforcement versus operant avoidance and light level.

Authors:  Ronald McGregor; Ming-Fung Wu; Grace Barber; Lalini Ramanathan; Jerome M Siegel
Journal:  J Neurosci       Date:  2011-10-26       Impact factor: 6.167

2.  Prostanoid receptor gene expression profile in human trabecular meshwork: a quantitative real-time PCR approach.

Authors:  W Kamphuis; A Schneemann; L M van Beek; A B Smit; P F Hoyng; E Koya
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-12       Impact factor: 4.799

3.  Increase of histaminergic tuberomammillary neurons in narcolepsy.

Authors:  Philipp O Valko; Yury V Gavrilov; Mihoko Yamamoto; Hasini Reddy; Johannes Haybaeck; Emmanuel Mignot; Christian R Baumann; Thomas E Scammell
Journal:  Ann Neurol       Date:  2013-12       Impact factor: 10.422

4.  A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.

Authors:  C Peyron; J Faraco; W Rogers; B Ripley; S Overeem; Y Charnay; S Nevsimalova; M Aldrich; D Reynolds; R Albin; R Li; M Hungs; M Pedrazzoli; M Padigaru; M Kucherlapati; J Fan; R Maki; G J Lammers; C Bouras; R Kucherlapati; S Nishino; E Mignot
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

5.  Greatly increased numbers of histamine cells in human narcolepsy with cataplexy.

Authors:  Joshi John; Thomas C Thannickal; Ronald McGregor; Lalini Ramanathan; Hiroshi Ohtsu; Seiji Nishino; Noriaki Sakai; Akhiro Yamanaka; Carly Stone; Marcia Cornford; Jerome M Siegel
Journal:  Ann Neurol       Date:  2013-09-10       Impact factor: 10.422

6.  Colocalization of orexin a and glutamate immunoreactivity in axon terminals in the tuberomammillary nucleus in rats.

Authors:  F Torrealba; M Yanagisawa; C B Saper
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

7.  Mu-opioid receptor-mediated depression of the hypothalamic hypocretin/orexin arousal system.

Authors:  Ying Li; Anthony N van den Pol
Journal:  J Neurosci       Date:  2008-03-12       Impact factor: 6.167

Review 8.  Orexin/hypocretin role in reward: implications for opioid and other addictions.

Authors:  Corey Baimel; Selena E Bartlett; Lih-Chu Chiou; Andrew J Lawrence; John W Muschamp; Omkar Patkar; Li-Wei Tung; Stephanie L Borgland
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

9.  Reduced number of hypocretin neurons in human narcolepsy.

Authors:  T C Thannickal; R Y Moore; R Nienhuis; L Ramanathan; S Gulyani; M Aldrich; M Cornford; J M Siegel
Journal:  Neuron       Date:  2000-09       Impact factor: 17.173

10.  Hypocretin (orexin) cell loss in Parkinson's disease.

Authors:  Thomas C Thannickal; Yuan-Yang Lai; Jerome M Siegel
Journal:  Brain       Date:  2007-05-09       Impact factor: 13.501

View more
  30 in total

1.  The number of lateral hypothalamus orexin/hypocretin neurons contributes to individual differences in cocaine demand.

Authors:  Caroline B Pantazis; Morgan H James; Brandon S Bentzley; Gary Aston-Jones
Journal:  Addict Biol       Date:  2019-07-11       Impact factor: 4.280

2.  Striking cessation of cataplexy by opioids.

Authors:  Claire E H M Donjacour; Gert Jan Lammers; Jerome M Siegel
Journal:  J Sleep Res       Date:  2018-10-12       Impact factor: 3.981

3.  Introduction to the Special Issue: "Making orexin-based therapies for addiction a reality: What are the steps from here?"

Authors:  Morgan H James; Gary Aston-Jones
Journal:  Brain Res       Date:  2020-01-10       Impact factor: 3.252

4.  Narcolepsy with resolution of cataplexy and persisting orexin deficiency.

Authors:  Danielle Wasserman; Claudio L A Bassetti; Ivana Rosenzweig
Journal:  J Clin Sleep Med       Date:  2020-08-15       Impact factor: 4.062

5.  The orexin-1 receptor antagonist SB-334867 reduces motivation, but not inhibitory control, in a rat stop signal task.

Authors:  Joost Wiskerke; Morgan H James; Gary Aston-Jones
Journal:  Brain Res       Date:  2019-04-16       Impact factor: 3.252

6.  Intermittent self-administration of fentanyl induces a multifaceted addiction state associated with persistent changes in the orexin system.

Authors:  Jennifer E Fragale; Morgan H James; Gary Aston-Jones
Journal:  Addict Biol       Date:  2020-08-14       Impact factor: 4.280

7.  Demand elasticity predicts addiction endophenotypes and the therapeutic efficacy of an orexin/hypocretin-1 receptor antagonist in rats.

Authors:  Morgan H James; Hannah E Bowrey; Colin M Stopper; Gary Aston-Jones
Journal:  Eur J Neurosci       Date:  2018-10-14       Impact factor: 3.386

8.  Chronic ketamine abuse is associated with orexin-A reduction and ACTH elevation.

Authors:  Ming-Chyi Huang; Chun-Hsin Chen; Lian-Yu Chen; Hu-Ming Chang; Chih-Ken Chen; Shih-Ku Lin; Ke Xu
Journal:  Psychopharmacology (Berl)       Date:  2019-08-03       Impact factor: 4.530

9.  Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats.

Authors:  Joaquin E Douton; Corinne Augusto; Brooke Stoltzfus; Nurgul Carkaci-Salli; Kent E Vrana; Patricia S Grigson
Journal:  Behav Pharmacol       Date:  2021-06-01       Impact factor: 2.293

10.  Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.

Authors:  Andrew S Huhn; Patrick H Finan
Journal:  Exp Clin Psychopharmacol       Date:  2021-06-10       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.